January is usually slow over the last couple of years with Noble investment conference, CEO conference, and Biotech Show case (which is a regular, annual outing. I don't see any imminent important scientific conferences where OncoSec would release any kind of important data (Punits past protocol, but new CEO may direct differently).
February was a good one last year and was active with:
February 27, 2017 | OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab
February 24, 2017 | OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York City
February 23, 2017 | OncoSec Announces Positive Phase II Data Demonstrating Company’s ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients
February 8, 2017 | OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February
But provides a better runway where we can better expect New data
March 2, 2017 | OncoSec to Host Second Quarter Financial Conference Call on March 16, 2017
March 7, 2017 | OncoSec to Present at Scientific and Investment Conferences in MarchMarch 28, 2017 | OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017
March 14, 2017 | OncoSec Announces First Technology Access Program Agreement with Inhibrx
March 16, 2017 | OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2017
March 21, 2017 | OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models
With this quick review, it's looking like from Feb through June hold a lot of potential opportunities for data like at the American Assoc. Cancer Research (AACR) on April 14-18, 2018, for which abstracts were to be submited by this Dec. 1, 2017., FDA rulings, collaborations and PISCES trial at ASCO, June 1-5, 2018. If OncoSec submits an abstract for that it must be submitted by February 13th, and late-breaking submitions by February 14th but before March 15.
Also there is A
